title: Chimaeric antigen receptor T-cell therapy for tumour immunotherapy.
abstract: Chimaeric antigen receptor (CAR) T-cell therapies, as one of the cancer immunotherapies, have heralded a new era of treating cancer. The accumulating data, especially about CAR-modified T cells against CD19 support that CAR T-cell therapy is a highly effective immune therapy for B-cell malignancies. Apart from CD19, there have been many trials of CAR T cells directed other tumour specific or associated antigens (TSAs/TAAs) in haematologic malignancies and solid tumours. This review will briefly summarize basic CAR structure, parts of reported TSAs/TAAs, results of the clinical trials of CAR T-cell therapies as well as two life-threatening side effects. Experiments in vivo or in vitro, ongoing clinical trials and the outlook for CAR T-cell therapies also be included. Our future efforts will focus on identification of more viable cancer targets and more strategies to make CAR T-cell therapy safer.
authors.affiliation: Department of Chemotherapy, Jiangsu Cancer Hospital Affiliated to Nanjing Medical University, Jiangsu Institute of Cancer Research, Nanjing 210009, China.
authors.forename: Huan-Huan
authors.initials: HH
authors.lastname: Sha
authors.affiliation: Department of General Surgery, The First Clinical School of Nanjing Medical University, Nanjing 210009, China.
authors.forename: Dan-Dan
authors.initials: DD
authors.lastname: Wang
authors.affiliation: Department of Chemotherapy, Jiangsu Cancer Hospital Affiliated to Nanjing Medical University, Jiangsu Institute of Cancer Research, Nanjing 210009, China.
authors.forename: Da-Li
authors.initials: DL
authors.lastname: Yan
authors.affiliation: Department of Chemotherapy, Jiangsu Cancer Hospital Affiliated to Nanjing Medical University, Jiangsu Institute of Cancer Research, Nanjing 210009, China.
authors.forename: Yong
authors.initials: Y
authors.lastname: Hu
authors.affiliation: Department of General Surgery, The Fourth Clinical School of Nanjing Medical University, Nanjing 210009, China.
authors.forename: Su-Jin
authors.initials: SJ
authors.lastname: Yang
authors.affiliation: Department of Chemotherapy, Jiangsu Cancer Hospital Affiliated to Nanjing Medical University, Jiangsu Institute of Cancer Research, Nanjing 210009, China.
authors.forename: Si-Wen
authors.initials: SW
authors.lastname: Liu
authors.affiliation: Department of Chemotherapy, Jiangsu Cancer Hospital Affiliated to Nanjing Medical University, Jiangsu Institute of Cancer Research, Nanjing 210009, China jifeng_feng@163.com.
authors.forename: Ji-Feng
authors.initials: JF
authors.lastname: Feng
mesh_terms: D019264:Adoptive Transfer / Q000009:adverse effects / Q000379:methods; D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects / Q000379:methods*; D009369:Neoplasms / Q000098:blood supply / Q000276:immunology / Q000628:therapy*; D009389:Neovascularization, Pathologic / Q000276:immunology / Q000628:therapy; D011487:Protein Conformation; D011948:Receptors, Antigen, T-Cell / Q000737:chemistry / Q000276:immunology / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000276:immunology* / Q000637:transplantation
chemical_list: D000951:Antigens, Neoplasm; C000605956:CD19-specific chimeric antigen receptor; D011948:Receptors, Antigen, T-Cell
keywords: T cells; chimeric antigen receptor; immunotherapy; tumor specific or associated antigens